UbiQ, founded in 2010 as a spin-out of the Netherlands Cancer Institute, develops and commercializes ubiquitin research tools, enabling drug discovery in the rapidly expanding ubiquitin field. Access to well defined ubiquitinated peptides and conjugates is of paramount importance for screening assays for the identification of new drugs, as well as for fundamental research and structural studies. Find out about how our reagents enable research at www.ubiqbio.com

Expertise: Reagent development in the ubiquitin field, using automated solid phase peptide synthesis and the application of warheads.